Table 1.
Tissues analyzed | Drug(s) | Condition | γ-H2AX detection | Phase | References |
---|---|---|---|---|---|
PBMCs | Clofarabine and cyclophosphamide | Refractory acute leukemias | FACS | I | [64] |
PBMCs/tumor biopsies | SJG-136 | Solid tumours | M | I | [65] |
AML marrow blasts | Combination of tipifarnib and etoposide | AML | FACS | I | [64] |
PBMCs | Combination of 5-azacytidine and entinostat | MDS, chronic myelomonocytic leukemia, and AML | I | I | [68] |
Plucked eye-brows | Olaparib (AZD2281) | Breast cancer | M | I | [39] |
CTCs/PBMCs | Combination of veliparib (ABT-888) with topotecan | Solid tumours and lymphomas | M | I | [67] |
ClinicalTrials.gov | |||||
Tissues analyzed | Drug(s) | Condition | γ-H2AX detection | Phase | ClinicalTri als.gov identifier |
PBMCs, skin, hairs | Veliparib (ABT-888) | Breast, ovarian, pancreatic, prostate cancers; BRCA1, BRCA2 mutations carriers | N/S | I | NCT008927 36 |
Tumor biopsies | 7-t-butyldimethylsilyl-10-hydroxycamptothecin | Solid malignancies | M/I | I | NCT012023 70 |
N/A | BSI-201 (Iniparib) | Advanced solid tumours | N/S | I | NCT011618 36 |
N/A | Combination of BSI-201 and temozolomide | Glioblastoma | N/S | I, II | NCT006877 65 |
N/A | BSI-201 (Iniparib) | Ovarian cancer | N/S | II | NCT010331 23 |
N/A | TH-302 | Glioma | M/I | II | NCT014036 10 |
N/A | Combination of gemcitabine, carboplatin and BSI-201 | Triple negative breast cancer | N/S | II | NCT008139 56 |
N/A | Combination of gemcitabine/carboplatin plus BSI-201 | Breast cancer | N/S | III | NCT009386 52 |